A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Recruiting
Madrigal Pharmaceuticals, Inc.
Phase 3
2019-03-28
A double-blind placebo controlled randomized Phase 3 study to determine if 80 or 100 mg of
MGL-3196 as compared with placebo resolves NASH on liver biopsy and prevents progression to
cirrhosis and/or advanced liver disease
A Phase 3 Study to Evaluate the Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease (NAFLD) Patients
Recruiting
Madrigal Pharmaceuticals, Inc.
Phase 3
2019-12-16
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and
tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching
placebo. 100 patients will be enrolled in a 100 mg open-label arm.
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Recruiting
Madrigal Pharmaceuticals, Inc.
Phase 3
2021-07-09
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and
Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
A Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis
Not yet recruiting
Madrigal Pharmaceuticals, Inc.
Phase 3
2022-08-01
This study will determine the effect of oral 80 mg resmetirom administered once daily on
participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by
measuring the time to experiencing a Composite Clinical Outcome event.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
